Jose Pablo Berros
Overview
Explore the profile of Jose Pablo Berros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Revuelta A, Mihic L, Castillo A, Marino A, Mateos L, Iglesias C, et al.
Sci Rep
. 2025 Jan;
15(1):3512.
PMID: 39875398
Totally implantable central venous catheters (CVCs) are widely used in the management of patients with malignant diseases. Conventionally, port implantations were carried out by general surgeons and vascular radiologists. In...
2.
Garcia Del Muro X, Maurel J, Martinez Trufero J, Lavernia J, Lopez Pousa A, De Las Penas R, et al.
Invest New Drugs
. 2018 Mar;
36(3):468-475.
PMID: 29527631
Background Sorafenib is a potent targeted-therapy that blockades angiogenesis and has demonstrated activity against some sarcoma subtypes. Preclinical studies suggested that treatment with sorafenib plus cytotoxic agents could result in...
3.
Lopez C, Esteban E, Berros J, Pardo P, Astudillo A, Izquierdo M, et al.
Clin Genitourin Cancer
. 2012 Sep;
10(4):262-70.
PMID: 22959659
Background: The purpose of this study was to evaluate prognostic factors in patients with RCC. Materials And Methods: The expression of several biomarkers were measured by immunohistochemistry (IHC), together with...
4.
Lopez C, Esteban E, Astudillo A, Pardo P, Berros J, Izquierdo M, et al.
Invest New Drugs
. 2012 May;
30(6):2443-9.
PMID: 22644070
Introduction: The analysis of predictive factors of response may aid in predicting which patients with advanced renal cell carcinoma (RCC) would be good candidates for systemic treatments. Materials And Methods:...
5.
Crespo G, Sierra M, Losa R, Berros J, Villanueva N, Fra J, et al.
Int J Gynecol Cancer
. 2011 Mar;
21(3):478-85.
PMID: 21436695
Introduction: Pegylated liposomal doxorubicin (PLD) is currently the reference treatment for platinum-resistant ovarian cancer. The combination of PLD and gemcitabine and the administration of gemcitabine at a fixed dose rate...
6.
Muriel C, Esteban E, Corral N, Fonseca P, Luque M, Berros J, et al.
Clin Transl Oncol
. 2010 Aug;
12(8):562-7.
PMID: 20709657
Introduction: For nearly the past two decades, cytokines (CKs) have been the only systemic treatment option available for advanced renal cell carcinoma (RCC). In recent years, tyrosine kinase inhibitors (TKIs)...
7.
Gonzalez E, Villanueva N, Fra J, Berros J, Jimenez P, Luque M, et al.
Invest New Drugs
. 2010 May;
29(6):1459-64.
PMID: 20464446
Topotecan, a semi-synthetic camptothecin analogue with topoisomerase I interaction, has shown to be an active agent in the treatment of advanced refractory lung cancer. This paper describes the authors' experience...